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1  |  INTRODUC TION
Pain is “an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such 
damage.”1 Pain, and specifically its treatment, is a major issue fac-
ing healthcare systems globally. In the US, the average annual cost 
associated with pain is $600 billion.2 Chronic pain is undertreated 
in 80% of cases.3 Opioids are the most effective compounds for al-
leviating severe pain across a wide range of conditions, for exam-
ple, acute pain in response to injury or chronic pain in response to 
inflammatory disease or cancer. However, opioid use is associated 
with side effects that become more severe with increased use, for 
example, severe drowsiness and breathing difficulties. Furthermore, 
decreasing analgesic efficacy is observed clinically with prolonged 
use of any strong opioid; this is a combination of tolerance to their 
analgesic effect and the development of opioid- induced hypersen-
sitivity (OIH) within pain signaling pathways. Tolerance is defined as 
a decreased efficacy following repeated administration,4 whereas 
OIH is a state of increased pain sensitivity.5 These can be overcome 
by increased dosage; however, this increases the risk of more severe 
side effects (e.g., respiratory depression). Thus, a vicious circle ex-
ists, and patients are often faced with a choice between side effects 
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Abstract
Opioids are a commonly prescribed and efficacious medication for the treatment of 
chronic pain but major side effects such as addiction, respiratory depression, anal-
gesic tolerance, and paradoxical pain hypersensitivity make them inadequate and 
unsafe for patients requiring long- term pain management. This review summarizes 
recent advances in our understanding of the outcomes of chronic opioid adminis-
tration to lay the foundation for the development of novel pharmacological strate-
gies that attenuate opioid tolerance and hypersensitivity; the two main physiological 
mechanisms underlying the inadequacies of current therapeutic strategies. We also 
explore mechanistic similarities between the development of neuropathic pain states, 
opioid tolerance, and hypersensitivity which may explain opioids’ lack of efficacy in 
certain patients. The findings challenge the current direction of analgesic research 
in developing non- opioid alternatives and we suggest that improving opioids, rather 
than replacing them, will be a fruitful avenue for future research.
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or inadequate analgesia. In addition, opioid- tolerant patients require 
significantly longer lengths of stay in hospital and have higher read-
mission rates compared with patients not on opioids,6 contributing 
to opioids’ economic burden. Therefore, there is an unmet clinical 
need to address tolerance.
Non- opioid painkillers currently available either do not offer 
sufficient analgesia (e.g., non- steroidal anti- inflammatory drugs 
[NSAIDs])	or	are	only	efficacious	in	specific	pain	condition	(e.g.,	ga-
bapentinoids in neuropathic pain), and are also limited by their own 
adverse	 side-	effects	 (e.g.,	 gastrointestinal	 bleeding	 with	 NSAIDs).	
An	 alternative	 approach	 is	 improving	 opioids	 by	 reducing	 the	 de-
velopment of opioid tolerance and OIH, increasing their long- term 
efficacy.
This review will explore the proposed mechanisms of OIH and 
tolerance and identify areas of therapeutic potential that may im-
prove the use of currently available opioids. Furthermore, it will 
discuss mechanistic similarities between the development of opi-
oid tolerance/OIH and certain neuropathic pain conditions which 
may provide an explanation for opioids’ lack of efficacy in some 
conditions.
2  |  OPIOID SIGNALING
The analgesic properties of opium, an extract from the Papaver som-
niferum poppy, and from which modern opiates (such as morphine) 
are derived, have been recognized for centuries. This beneficial ef-
fect is offset by a variety of side- effects including constipation, res-
piratory depression, dependence, addiction, hypersensitivity, and 
tolerance.
Opioids exert their action through interaction with the superfam-
ily of heterotrimeric opioid G- protein- coupled receptors (GPCRs); 
the mu (MOR), delta (DOR), and kappa (KOR) opioid receptors. The 
most clinically relevant are MORs; it is through these receptors that 
both natural opiates and synthetic opioids, such as fentanyl, exert 
analgesia and their side- effects. This is confirmed by numerous 
studies using MOR- knockout mice which no longer respond to mor-
phine to produce analgesia or its side- effects.7 In contrast, DOR- 
knockouts retain full morphine analgesia,8 and more recent studies 
have suggested that while activation of KOR can cause analgesia, 
extremely high opioid doses were required for mild analgesia, and 
further increase in dosage was not possible due to the paradoxical 
pain hypersensitivity observed.9
Attempting	 to	 improve	 opioid	 analgesia	 is	 not	 a	 novel	 idea.	
Strategies to reduce side- effects associated with prolonged opi-
oid use, such as the use of KOR and DOR agonists or peripheral 
MOR antagonists, have been trialed but with limited success. 
DOR and KOR agonists produce limited analgesia in only specific 
inflammatory conditions, and KOR agonists may be specific for 
visceral pain.10– 12	 Also,	 KOR	 agonists	 have	 distinct	 central	 ner-
vous system (CNS) side- effects, such as dysphoria, sedation, and 
psychosis, when compared to those traditionally associated with 
opioids.13 Peripheral MOR antagonism acts on the gastrointestinal 
(GI) system, only reducing constipation and preserving centrally 
mediated side- effects.14 This highlights an unmet clinical need to 
reduce the critical CNS- mediated side effects of opioids (tolerance 
and OIH).
3  |  PAIN SIGNALING PATHWAYS
Pain processing is initiated by the activation of nociceptive affer-
ent	neurons	(C	and	Aδ fibers). The afferents terminate in the dorsal 
horn (DH) of the spinal cord, where they synapse with second- order 
neurons, either projecting neurons that carry the signal to supraspi-
nal regions, or interneurons within the DH which later synapse onto 
projecting neurons. This synapse is the first possible point of regula-
tion of pain signaling, occurring through inhibitory interneurons and 
descending control. Regulation is through inhibitory neurotransmit-
ters	(NTs)	such	as	gamma-	aminobutyric	acid	(GABA)	or	endogenous	
opioids which create a “gate” for incoming pain signals.15 Therefore, 
opioid receptors are present on primary afferent and in the DH, 
and local administration of opioids into the spinal cord induces 
analgesia.16
Projection neurons exit the DH toward supraspinal regions im-
portant for the conscious sensation of pain. For example, the so-
matosensory cortex for localization and intensity and the cingulate 
cortex, insula, and amygdala for the cognitive and emotional com-
ponents associated with painful stimuli. This ascending system also 
makes a crucial connection with regions of the midbrain and brain-
stem that feed into the descending inhibitory pathways (Figure 1).
The descending pain pathways are primarily antinociceptive, the 
most studied being the periaqueductal gray- rostroventral medulla- 
dorsal	horn	(PAG-	RVM-	DH)	circuit	(Figure	2),	but	activation	of	cer-
tain supraspinal regions (e.g., the anterior cingulate cortex) can also 
give rise to descending facilitation which can counteract descending 
inhibition	from	the	PAG	and	RVM,	or	contribute	to	pain	hypersen-
sitivity in certain injury states.18,19	The	PAG	may	also	be	involved	in	
some forms of descending facilitation and two classes of nociceptive 
modulating neurons have been noted in this region.20
The	RVM	 is	 the	 central	 hub	 for	 the	descending	 systems	 (both	
facilitatory and inhibitory). Three populations of neurons projecting 
to	the	spinal	cord	from	the	RVM	have	been	identified	from	animal	
electrophysiological experiments (ON- cells, OFF- cells, and neutral 
cells) on the basis of their pronociceptive/antinociceptive effects 
following stimulation.21 Prior to a tail- flick reflex, ON- cells show a 
burst in activity while the firing rate of OFF- cells is dramatically re-
duced.22 Signaling of painful stimuli is associated with increased ac-
tivity in ON- cells, necessary for the acute hypersensitivity observed 
in animals, and suppression of antinociceptive OFF- cells.23 Opioid 
receptors	are	also	located	throughout	the	PAG-	RVM-	DH	descend-
ing system and can be activated endogenously to induce analgesia, 
for example, during the phenomena of stress- induced analgesia.24 
Therefore, opioid receptors are expressed consistently in the pain 
processing pathways (ascending and descending), perhaps explain-
ing their high efficacy as analgesic targets.
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4  |  SITES OF OPIOID -  INDUCED 
ANALGESIA
There is compelling evidence suggesting the supraspinal action of 
exogenous opioids is primarily responsible for their antinociceptive 
effect. Direct administration of the MOR antagonist, naloxone, into 
the	ventrolateral	PAG	 (vlPAG)	blocks	 the	antinociceptive	effect	of	
systemically administered morphine,25 and administration of a MOR 
agonist	into	the	vlPAG	produces	analgesia	in	rats	that	is	blocked	by	
systemically administered naloxone.26	These	data	suggest	the	vlPAG	




interneurons have tonic activity. Upon agonist binding to MORs, the 
activity of these neurons is decreased.27,28	Microdialysis	of	the	PAG	
following	 acute	morphine	 administration	 showed	decreased	GABA	
levels.29 More recent studies using chemogenetic manipulation of 
vlPAG	neural	activity	provide	further	support	for	this	crucial	mech-
anism toward opioid- induced analgesia.30 The selective inhibition of 
GABAergic	neurons	or	 selectively	activating	glutamatergic	 (output)	
neurons	in	the	vlPAG	mimicked	the	antinociceptive	effects	of	opioids.
The	OFF-	cell	 population	of	RVM	neurons	 appears	 to	primarily	
consist	of	Glycine/GABAergic	neurons	that	act	diffusely	in	the	dor-
sal horn to decrease excitability.31,32 Some OFF- cells may provide 
glutamatergic	 projections	 to	 endogenous	 opioid/GABA	 releasing	
inhibitory interneurons in the dorsal horn33 to provide a mechanism 
for precise inhibition of specific pain inputs.
Furthermore, microinjection of MOR agonists into the 
RVM	 directly	 inhibits	ON-	cells.34,35 This combination of indi-
rect disinhibition of OFF- cells and direct inhibition of ON- cells 
projecting to the dorsal horn appears to be the primary mech-
anism of opioid analgesia. Khalefa et al. attempted to quantify 
the relative contributions of peripheral, spinal, and supraspi-
nal MORs to the analgesic effects of systemic opioids in a rat 
model of inflammatory pain.16 In agreement with the previous 
experiments discussed, antagonism of the supraspinal effects 
of fentanyl and morphine with intracerebrovascular naloxone 
attenuated their antinociception by 70%– 80% (compared with 
a 20%– 30% attenuation following intrathecal administration). 
Therefore,	the	action	of	exogenous	opioids	at	specific	loci	(PAG	
and	RVM)	in	the	descending	pain	modulatory	system	is	crucial	
for opioid- induced analgesia, and it follows that tolerance to 
their analgesia is due to adaptations in this opiate- responsive 
neural circuit.
F I G U R E  1 Anatomy	of	the	pain	
processing pathway (From Cellular 
and Molecular Mechanisms of Pain, 
Basbaum et al., Cell, 2009, 139:267– 
284. With permission from Elsevier).17 
Primary afferent nociceptors convey 
noxious information to projecting 
neurons in the dorsal horn (DH) of the 
spinal	cord.	A	subset	of	these	projecting	
neurons transmits information to the 
somatosensory cortex via the thalamus 
providing physical information about the 
painful stimulus (the primary ascending 
pathway, in green). Other projection 
neurons (in blue) relay via brainstem 
structures to engage the insular and 
cingulate cortex, contributing to the 
affective and cognitive components of 
pain. The ascending information is also 
able to interact with several other brain/
brainstem areas, such as the rostral 
ventral	medulla	(RVM)	and	midbrain	
periaqueductal	gray	(PAG)	to	engage	
descending feedback systems that 
regulate the output of projecting neurons 
in the DH (in orange)
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5  |  MOLECUL AR MECHANISMS OF ACUTE 
OPIOID ANALGESIA
The	 PAG	 is	 an	 important	 region	 for	 opioid	 analgesia.	 MORs	 are	
located	on	GABAergic	 interneurons,	and	are	Gi/o- coupled GPCRs. 
Following acute opioid binding, the Gβγ subunit dissociates from 
the Gαi subunit and both are involved in independent signaling 
cascades (Figure 3). Gαi	 inhibits	 adenylyl	 cyclase	 (AC)	 which	 de-
creases	 cyclic	 adenosine	monophosphate	 (cAMP)	 levels	 resulting	
in	 a	 range	of	 cellular	 effects,	 such	 as	decreased	protein	 kinase	A	
(PKA)	activation.	 Interestingly,	acute	morphine	administration	ap-
pears to rely on the actions of the Gβγ subunit to hyperpolarize 
GABAergic	 interneurons	 (via	 activation	 of	 potassium	 channels)	
and	 directly	 inhibit	 voltage-	gated	 calcium	 channels	 (VGCCs)	 in	 a	
membrane- delimited mechanism. This involves the QXXER motif 
of the I- II loop, the intracellular N- terminus, and the β subunit of 
the	VGCC.36– 38	Inhibition	of	VGCCs	by	Gβγ	reduces	GABA	release	
from the synaptic terminal.28	 Reduced	 GABA	 release	 disinhibits	
PAG	output	to	the	RVM,	increasing	spontaneous	firing	of	OFF-	cells	
responsible for antinociception.
6  |  OPIOID TOLER ANCE AND OPIOID - 
INDUCED HYPERSENSITIVIT Y ARE THE 
RESULTS OF ADAPTIVE CHANGES IN PAIN 
PROCESSING PATHWAYS
Tolerance and OIH develop with chronic opioid administration. Both 
are long- term adaptations that may persist after opioid usage has 
stopped. The net effect of tolerance and OIH is responsible for the 
reduction in opioid efficacy observed clinically. The sites and mecha-
nism of tolerance and OIH development must be understood before 
rational attempts at targeting them can be made.
6.1  |  Sites of tolerance development
Similar levels of analgesic tolerance develop following repeated sys-
temic	or	local	administration	of	morphine	into	the	vlPAG.	Specific	acti-
vation	of	vlPAG	output	neurons	by	microinjecting	bicuculline	(a	GABA	
antagonist) and kainite (an excitatory amino acid) did not produce tol-
erance in rats,42 suggesting that repeated activation of output neurons 
F I G U R E  2 The	PAG-	RVM	descending	
system under normal conditions. In the 
naïve	state,	GABAergic	interneurons	
are	tonically	active,	thus	both	PAG	
output neurons and OFF- cells have low 
spontaneous	firing	rates.	Activity	in	
OFF- cells causes antinociception, and 
activity in ON- cells represents descending 
facilitation of pain. The normal activity of 
ON- cells is also low, such that the overall 
balance between ON- cell and OFF- cell 
output to the dorsal horn (DH) is equal 
and there is no net hypersensitive or 
antinociceptive state in the individual






as	activity	 in	RVM	OFF-	cells	 is	 intrinsically	 linked	to	PAG	output	neuron	
activity.	Acute	opioid	administration	disrupts	the	activity	of	ON-	and	OFF-	
cells in response to painful stimuli. However, due to tolerance associated 
with chronic opioid administration, these ON- and OFF- cells respond as if 
there was no opioid stimulation.45	An	increase	in	ON-	cell	activity	also	oc-
curs following chronic opioid use which appears to counteract opioid anal-




Therefore, tolerance develops in numerous sites of the descending system, 
but	the	most	significant	involves	GABAergic	interneurons	in	the	PAG.
6.2  |  Mechanisms of tolerance in the PAG
When considering potential homeostatic adaptations involved in tol-
erance, counteracting the direct downstream signaling pathways of 
MOR activation would lead to decreased responsiveness of the sys-




Chronic morphine use produces adaptations contributing to opioid- 
tolerance within MORs’ downstream signaling pathways (Figure 4). 
For	 example,	 whereas	 acute	 morphine	 inhibits	 AC,	 reducing	
cAMP	 levels,	 chronic	 morphine	 upregulates	 cAMP	 via	 “superac-
tivation”	 of	 AC.	 Compensatory	 activation	 of	 AC	 increases	 cAMP	
F I G U R E  3 Intracellular	signaling	in	naïve	PAG	GABAergic	interneurons,	and	following	acute	morphine	administration	(reproduced	
with	permission	from	Lueptow	et	al.	201839). In the naïve state.	GABAergic	interneurons	are	tonically	active	and	release	the	inhibitory	
neurotransmitter	GABA.	GABA	acts	through	GABAA	receptors	on	PAG	output	neurons.	GABAA receptors are inhibitory by causing an influx 
of	chloride	ions	which	hyperpolarizes	and	therefore	inhibits	the	PAG	output	neurons.	Following acute morphine administration. MORs initiate 
a variety of downstream signaling cascades in the interneurons. Postsynaptically, MORs activate G- protein- coupled inwardly rectifying 
potassium ion channels (GIRKs), hyperpolarizing the neuron. Both Gαi and Gβγ are important in regulating the activity of GIRK. Gαi directly 
binds to the GIRK channel, stabilizing it and priming it for Gβγ activation.40Presynaptically, MORs inhibit voltage- gated calcium channels 
(VGCCs)	via	the	Gβγ subunit. Inhibition by Gβγ is voltage- dependent and large or repeated depolarizations of the presynaptic terminal could 
overcome the inhibition.41 Gβγ	also	activates	voltage-	gated	potassium	channels	(Kv's)	via	a	mechanism	involving	phospholipase	A	(PLA).	
The overall effect of decrease calcium ion influx and increased potassium ion efflux is hyperpolarization and inhibition of neurotransmitter 
release,	therefore	decreasing	GABA-	mediated	inhibition	of	output	neurons
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concentrations in the neurons, which has a variety of cellular ef-
fects.	Of	 significance,	 phosphorylation	 of	VGCCs	 by	 PKA	 causes	
a leftward shift in their activation curve (Figure 5). Heightened 
calcium	 conductance	 increases	 inhibition	 of	 PAG	 output	 neurons	
via	 GABAA receptor activation. Supporting this, potassium chan-
nel	blockers	abolished	acute	opioid	presynaptic	inhibition	of	GABA	
release	 in	 the	PAG	but	 had	no	effect	 on	 the	 increased	 inhibitory	
synaptic	currents	observed	with	chronic	opioids,	whereas	PKA	in-
hibitors did block this.47 Therefore, acute opioid antinociception 








fecting	 acute	 opioid	 efficacy,	 based	 on	 animal	 studies.	 A	 recent	 ex-
periment	demonstrated	that	repeated	activation	of	AC	in	the	vlPAG	by	
forskolin	mimics	morphine	tolerance,	and	blocking	AC	with	an	inhibitor	
reverses morphine tolerance.53	 In	theory,	 inhibition	of	AC	would	pre-
vent	the	left-	ward	shift	of	VGCCs	caused	by	AC	superactivation	with-
out effecting antinociception via Gβγ- dependent signaling pathways. 
Furthermore,	AC	inhibition	may	provide	the	added	benefit	of	reversing	
many of the withdrawal symptoms associated with cessation of chronic 
opioid use.53	Thus,	AC	may	be	a	good	target	to	reduce	tolerance	devel-
opment.	A	major	limitation	of	this	method	is	the	inability	to	specifically	
F I G U R E  4 Intracellular	adaptations	
produced by chronic morphine use in 
GABAergic	interneuron	in	the	PAG	
(reproduced with permission from 
Lueptow	et	al.39). Postsynaptically, there 
may be some uncoupling between the 
G proteins and MORs, a process distinct 
from acute homologous desensitization 
(Melief et al.49; Bruchas et al.50), 




calcium conductance. The overall effect 
is	increased	GABA	release	and	therefore	
stronger	inhibition	of	PAG	output	neurons
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target	AC	inhibitors	to	important	brain	regions	such	as	the	PAG	in	hu-
mans. Systemic administration would result in too many side- effects and 
would interfere with many other drugs on the market. Microinjections 
are used in animal studies, but this is not viable in humans requiring long- 
term opioid use. Targeted drug delivery systems are currently not reli-
able, but the significant amount of modern research into new delivery 
vehicles	for	active	targeting	makes	the	potential	use	of	AC	inhibitors	a	
very real possibility in the future.54	Alternative	methods	to	reduce	AC	
levels also exist, for example, targeting other Gi/o- receptors expressed 
on	the	same	MOR-	responsive	GABAergic	interneurons.	GABAB recep-









this could be achieved by targeting other Gi/o- coupled receptors on 
MOR-	expressing	 GABAergic	 interneurons.	 Manipulating	 the	 en-
docannabinoid system appears an ideal candidate. CB1 receptors 
are expressed in many of the same regions as MORs, and there is 
strong evidence to show that CB1 receptor agonists are capable of 
producing analgesia.57	Like	the	opioid	system,	endocannabinoids	are	
released as a neurotransmitter from specific neurons under certain 
stressful conditions.58 Targeting this system with exogenous can-
nabinoids overcomes the requirement for these specific conditions.
Like	 opioid	 receptors,	 CB1 receptors are Gi/o- coupled GPCRs. 
They	also	presynaptically	 inhibit	GABAergic	 synaptic	 transmission	
to	 disinhibit	 PAG	 antinociceptive	 output	 neurons.	However,	while	
MORs	 directly	 inhibit	 tonically	 active	 GABAergic	 interneurons	 in	
the	 PAG,59	 cannabinoid-	induced	 increases	 in	 PAG	 output	 appears	
to be dependent on metabotropic glutamate receptor 5 (mGlu5R) 
activity.	A	selective	mGlu5R	antagonist	microinjected	into	the	PAG	
completely blocked the effect of exogenous cannabinoid agonists 
on	PAG	cell	activity.60 This is consistent with previous findings that 
glutamate	can	produce	antinociception	in	the	PAG	via	postsynaptic	
F I G U R E  5 Calcium	conductance	through	VGCCs	in	naïve,	acute,	and	chronic	morphine/withdrawal	GABAergic	interneurons	in	the	PAG.	
The	average	resting	membrane	potential	in	PAG	interneurons	is	−60	mV.51	A,	the naïve neuron in blue. A modest level of calcium conductance 
(arbitrary	units,	AU)	is	present.	The	calcium	influx	triggers	calcium-	dependent	exocytosis	and	neurotransmitter	release.	Hence	naïve	PAG	
interneurons	tonically	release	GABA.	B,	acute morphine in red. Following	acute	activation	of	MOR,	inhibition	of	AC-	cAMP-	PKA	signaling	
results	in	dephosphorylation	of	VGCCs	and	direct	binding	of	Gβγ	causes	a	right-	ward	shift	in	the	activation	of	VGCCs.	Furthermore,	the	
opening	of	potassium	channels	by	morphine	hyperpolarizes	the	interneurons	(approximately	−70	mV).	The	combination	of	these	two	
factors	results	in	very	low	conductance	through	the	VGCCs	and	inhibition	of	GABA	release.	C,	chronic morphine in green. Superactivation 
of	AC	causes	overactivation	of	PKA	that	can	phosphorylate	VGCCs.	Phosphorylation	by	PKA	increases	the	probability	of	channel	opening,	
allowing for calcium influx even in hyperpolarized neurons52
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mGlu5Rs on output neurons.61 The source of this glutamate may be 
from	excitatory	glutamatergic	 interneurons	 in	 the	PAG.	Activation	
of	the	second	population	of	GABAergic	interneurons	expressing	CB1 
receptors	 (distinct	 from	MOR	 containing	GABAergic	 interneurons	
in	the	PAG)	disinhibits	the	glutamatergic	interneurons,	thus	increas-
ing	 the	activity	of	 the	PAG	output	neurons.	Supporting	 this,	 a	 re-
cent experiment found chemogenetic inhibition of CB1 expressing 
GABAergic	neurons	in	the	vlPAG	activated	glutamatergic	interneu-
rons	in	the	vlPAG,	producing	antinociception.62 Confirmation of this 
mechanism requires receptor expression studies to identify if CB1 
receptors	and	MORs	are	co-	expressed	in	PAG	GABAergic	interneu-
rons, or if they are found in distinct populations.
Cannabinoids	also	act	directly	in	the	RVM,	shifting	the	balance	
between	ON-	and	OFF-	cells	in	the	RVM	in	the	direction	of	the	ant-
inociceptive OFF- cells. Systemic administration of cannabinoids in-
hibits	RVM	ON-	cell	activity	and	 increases	OFF-	cell	activity.63 This 
mechanism	appears	to	be	via	direct	action	in	the	RVM.	CB1	receptor	
agonists increase the spontaneous activity of OFF- cells following 
microinjection	 into	 the	 RVM.64 This is distinct from the action of 
MOR	agonists	in	the	RVM.	Microinjection	of	morphine	to	the	RVM	
only depressed ON- cell activity, without effecting OFF- cell firing,34 
suggesting only ON- cells expressed MORs.33	As	such,	even	though	
the	end	result	of	CB1	agonists	on	the	PAG-	RVM	system	is	similar	to	
that of opioids (i.e., increased activity of OFF- cells and decreased ac-
tivity of ON- cells), cannabinoids may offer complementary analgesia 
when co- administered with opioids by shifting the balance between 
the	state	of	ON-	and	OFF-	cell	firing	at	both	the	level	of	the	PAG	and	
RVM,	 through	 mechanisms	 independent	 of	 MORs	 and	 bypassing	
opioid	tolerance	mechanisms	in	the	PAG.33
6.2.4  |  Cannabinoids	may	improve	the	efficacy	of	
opioids in certain neuropathic pain conditions
A	linear	circuit	involved	in	the	development	of	neuropathic	pain	has	
recently been described by Huang et al.65 (Figure 6).
This linear circuit interacts with the opioid- sensitive descending 
system.	PAG	projection	neurons	to	the	RVM	receive	excitatory	input	
from the medial prefrontal cortex (mPFC) and inhibitory input from 
GABAergic	 interneurons	 in	the	PAG.	The	balance	of	 these	two	 in-
puts dictates the level of descending pain modulation. Opioid action 
in	 the	PAG	disinhibits	output	neurons.	However,	 in	 some	cases	of	
neuropathic pain, decreased excitatory connections between the 
mPFC	and	vlPAG	means	the	action	of	opioids	alone	on	PAG	 inter-
neurons cannot cause substantial activation of the descending pain 
system. Essentially, the neuropathic condition itself has reduced the 
effectiveness	 of	 the	 PAG-	RVM-	DH	 antinociceptive	 system.	 This	
model suggested by Huang et al. outlines a potential synergistic role 
of cannabinoids and opioids in treating patients suffering from cer-
tain neuropathic conditions who do not receive adequate analgesia 
from opioids alone, by allowing for a greater level of descending pain 
inhibition. However, the current research in this area does not go be-
yond in- vitro studies and, moreover, specific neuropathic conditions 
which might be modulated by this circuit are unknown. Thus, more 
active research into this area is needed.
A	 recent	 meta-	analysis	 found	 a	 significant	 reduction	 in	 neu-
ropathic pain in patients receiving cannabinoid treatment.66 
Additionally,	the	use	of	cannabis	as	an	adjunct	to	opioids	may	pro-
vide greater cumulative relief of pain and allow for a reduction in 
opioid dose, decreasing opioid- related side- effects.67 Further clini-
cal trials are required to fully profile the side- effects of cannabinoid 
treatment and identify the types of pain they may be useful for. The 
recent legalization of cannabis in many countries and widespread 
availability make targeting the endocannabinoid system a compel-
ling avenue to pursue.
6.3  |  Sites of OIH development
Hyperalgesia has been reported in several laboratories following 
systemic opioid administration.68,69 Clinical data support this ex-
perimental evidence, for example, in patients detoxing from high 
opioid doses.70	A	prospective	trial	in	which	participants	were	given	
morphine for lower back pain also demonstrated measurable hyper-
algesia within one month.71 Therefore, OIH is a well- documented 
phenomenon, distinct from opioid tolerance, and unrelated to 
changes in underlying pain pathology. Often, the development of 
OIH is only observed following withdrawal from opioids, as high opi-
oid doses can mask the hyperalgesia.
The development of OIH involves a variety of independent 
adaptive changes in the opioid- responsive pain processing path-
ways. Chronic morphine administration increases the number of 
active	ON-	cells	 in	 the	RVM,	 likely	 causing	pain	 hypersensitivity.72 
Furthermore, OIH also incorporates sensitization of the ascending 
pro- nociceptive pathway; for example, increased activity of primary 
afferents within dorsal root ganglia and sensitization of spinal neu-
rons in the DH.73,74 Many of the mechanisms leading to OIH appear 
to alter synaptic plasticity between neurons, leading to a more pro-
nociceptive state in the body.
6.4  |  Mechanisms of OIH development in the RVM
Descending	facilitation	from	the	RVM	to	the	spinal	cord	is	important	
for the manifestation of OIH. Continuous morphine administration 
results in a hypersensitive state which can be reversed by lidocaine 
injection	into	the	RVM.75	The	mechanism	of	OIH	in	RVM	appears	to	




Microdialysis	 of	 rat	 RVMs	 following	 continuous	 systemic	 mor-
phine showed a fivefold increase in cholecystokinin (CCK) levels 
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compared with controls, suggesting that CCK release is one of 
the long- term signaling outcomes of morphine administration.76 
Furthermore,	activation	of	CCK	receptors	 in	 the	RVM	promoted	
mechanical and thermal hypersensitivity,76 whereas CCK antise-
rum or administration of receptor antagonists prevented this.77 
Therefore, activation of the CCK system by opioids may play a role 
in the development of OIH, and animal studies have shown the 
potential of CCK antagonists in attenuating this phenomenon. The 




CCK	 in	 the	 RVM	modulates	ON-	 and	OFF-	cell	 firing.	 CCK	 re-
ceptors are a group of Gi/o- coupled GPCRs, and activation hyperpo-
larizes neurons, reducing neurotransmitter release.78	Activation	of	
CCK	receptors	in	the	RVM	prevents	the	morphine-	induced	increase	
in OFF- cells activity.79	A	more	recent	study	found	CCK	microinjec-
tion	into	the	RVM	activated	ON-	cells,	perhaps	mediating	descend-
ing pain facilitation.80	 Activation	 of	 ON-	cells	 may	 be	 mediated	
through an excitatory Gq- coupled CCK receptor. The reliability of 
CCK- mediated activation of ON- cell firing has been questioned as 
many studies have failed to repeat this finding. One hypothesis is 
that higher doses of CCK activate ON- cells; Heinricher & Neubert 
(2004) used a concentration 3x higher than Heinricher et al. (2001).
Preliminary human evidence suggests that CCK is a viable target 
to improve opioids, with increased opioid efficacy being recognized 
as a novel side effect of proglumide (a non- selective CCK antago-
nist) in human volunteers.81 However, little progress has been made 
over the last 30 years in regard to clinical trials of CCK antagonists 
for this purpose. This lack of progress may be the consequence of 
insignificant results in humans due to redundancy within the “anti- 
opioid” system. Other neuropeptides, such as neuropeptide FF 
(NPFF), are also able to induce OIH and targeting only one anti- opioid 
may not significantly impact hypersensitivity in non- experimental 
models.82 Rather than targeting the neuropeptides directly, it may 
be useful to identify the MOR signaling cascades responsible for 
activating the anti- opioid systems with the hopes of discovering a 
common targetable pathway.
6.5  |  OIH in the spinal cord and peripheral 
nervous system
Numerous mechanisms for OIH have also been identified in the spi-
nal cord and peripheral nervous system including sensitization of 
primary afferents and enhanced glutamate release from these af-




Opioids can trigger pro- inflammatory cascades in astrocytes and 
microglia in the spinal cord, where they may contribute to OIH. 
Following opioid binding to the MOR, various intracellular signal 
pathways are activated leading to pro- inflammatory cytokine re-
lease and a shift in chloride activity from inhibitory to excitatory.84 
These adaptive changes mimic the development of hyperalgesia 
in various inflammatory and neuropathic pain conditions.85	 Acute	
F I G U R E  6 Linear	circuit	involved	
in the development of neuropathic 
pain (as described by Huang et al.65). 
Peripheral nerve injury augments 
basolateral	amygdala	(BLA)	inputs	onto	
GABAergic	interneurons	located	in	the	
medial prefrontal cortex (mPFC). This 
augmentation is the result of weakened 
endocannabinoid signaling. Decreased 
CB1 receptor density was observed in 
BLA-	originating	presynaptic	terminals.	
Increased activity in mPFC inhibitory 
interneurons leads to an overall inhibition 
of excitatory pyramidal cell output toward 
vlPAG	output	neurons.	The	net	effect	is	
decreased descending inhibition via the 
RVM	to	the	spinal	cord
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opioid administration is not sufficient, and chronic opioid use is re-
quired, for the activation of astrocytes and microglia.86,87
The contribution of neuroinflammatory cells has been demon-
strated using inhibitors of glial cell activity - either glial cell block-
ers or antagonists of the mediator's released (e.g., proinflammatory 
cytokine antagonists). Furthermore, cytokines and chemokines re-
leased may contribute to OIH. Chronic morphine upregulated C- X- C 
chemokine receptor type 4 (CXCR4) in nociceptors, and blockade 
with antagonists reversed OIH in rats.88 These neuroinflammatory 
molecules create ideal targets as many drugs targeting them are al-
ready available for use in the clinic.
6.5.2  | Microglia	activation	shifts	the	neuronal	
anion gradient making previously inhibitory 
synapses excitatory
Brain- derived neurotrophic factor (BDNF) is released from microglia fol-
lowing opioid binding and activates tropomyosin receptor kinase B (TrkB) 
on	DH	neurons,	inverting	the	polarity	of	current	activated	by	GABA.89,90 
Normally,	 influx	 of	 chloride	 through	 GABA	 receptors	 is	 inhibitory.	
However, morphine disrupts neuronal chloride homeostasis and instead, 
chloride	exits	through	activated	GABA	receptors	to	cause	depolariza-
tion. Gene- targeted mice in which BDNF was deleted from microglia did 
not develop hyperalgesia to morphine, but still developed tolerance, dis-
sociating the two phenomena.90 The mechanism of microglia- mediated 
OIH involves a pathway beginning with P2X- purinoceptor 4 (P2X4) re-
ceptors in microglia, and ends with downregulation of the potassium- 
chloride co- transporter (KCC2) in DH lamina I neurons (Figure 7). The 





Understanding the P2X4- BDNF- KCC2 pathway creates numer-
ous novel pharmacological targets to improve opioids by attenuating 
OIH. Importantly, the goal is to restore Cl−	extrusion	to	allow	GABA	
receptors to function normally. Furthermore, BDNF- TrkB signaling 
also appears important for the development of inflammatory and 
neuropathic pain conditions, so targeting this pathway may provide 
a dual role by acting as an opioid adjuvant to reduce OIH and improv-




The glutamatergic system in the DH is crucial for OIH by increasing 
the strength of synaptic transmission between neurons. Glutamate 
N-	methyl-	D-	aspartate	receptors	(NMDARs)	are	located	presynapti-
cally on primary afferents and postsynaptically on spinal DH neu-
rons,	so	are	well	placed	to	induce	long-	term	potentiation	(LTP)	in	the	
ascending pain processing pathway.93	 LTP	 produces	 a	 long-	lasting	
increase in signal transmission between two neurons.94 Opioids can 
activate	this	central	glutaminergic	system	via	sustained	NMDAR	ac-
tivity,	 inducing	LTP	and	sensitizing	DH	neurons.95 Supporting this, 
LTP	has	been	shown	to	occur	between	primary	afferent	C-	fibers	and	
neurons from the superficial layers of the DH.96
Administration	 of	 ketamine	 (a	 NMDAR	 antagonist)	 diminishes	
OIH in both rats and mice,68,97 supporting the role of glutamate 
in OIH. Electrophysiology recordings showed significantly in-
creased amplitude and frequency of excitatory postsynaptic cur-
rents evoked from primary afferents following chronic morphine, 
and this was attenuated by blocking protein kinase C (PKC) or with 
NMDAR	 antagonism.98 They hypothesized that chronic morphine 
administration	induced	PKC-	mediated	phosphorylation	of	NMDARs.	
Phosphorylation	 of	NMDARs	overcomes	 their	 characteristic	Mg2+ 
F I G U R E  7 The	P2X4-	BDNF-	KCC2	pathway	involved	in	OIH	(reproduced	with	permission	from	Trang	et	al.	2015).	The	binding	of	
morphine (or other MOR agonists) to MORs on spinal microglia activates pro- inflammatory cascades in the microglia. Microglia activation 
induces	P2X4	receptor	upregulation,	and	morphine	causes	the	release	of	BDNF	through	ATP-	mediated	stimulation	of	P2X4	receptors.	BDNF	
acts through TrkB on dorsal horn lamina I neurons to downregulate the expression of KCC2. This disrupts chloride homeostasis in the DH by 
preventing	chloride	efflux	via	KCC2.	The	increased	intracellular	chloride	concentration	in	lamina	I	neurons	shifts	GABA	receptor	activation	
from inhibitory to excitatory90
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block, surpassing the need for depolarization, to allow Ca2+ conduc-
tance.	PKC	also	promotes	NMDAR	trafficking	to	the	plasma	mem-
brane.99 Increased Ca2+	 flux	 through	NMDAR	causes	activation	of	
Ca2+/calmodulin-	dependent	 protein	 kinase	 II,	 PKA	 and	 neuronal	
nitric oxide synthase (nNOS), and further activation of PKC. While 
the effects of these specifically for analgesia are not clear, their 
effects in other neuronal circuits may provide an insight into their 
functions. For example, activation of nNOS increases the synthe-
sis	of	nitric	oxide	(NO)	from	L-	arginine.	NO	in	presynaptic	terminals	
increases glutamate neurotransmitter release.100 This supports a 
potential	 role	of	PKC	 inhibitors	and	NMDAR	antagonists	 in	reduc-
ing OIH. Furthermore, chronic morphine decreases the glutamate 
transporters	glutamate	aspartate	transporter	EAAT1	(GLAST-	1)	and	
glutamate	transporter	EAAT2	(GLT-	1)	activity	in	neurons,	sustaining	
the increased synaptic glutamate concentration and further enhanc-
ing glutamate signaling in the DH.101
While	NMDAR	antagonist	have	been	shown	effective	at	increas-
ing opioid potency in animal models, they have not passed clinical 
trials for this purpose due to major side- effects such as hallucina-
tions and drowsiness,102	 the	result	of	excessive	NMDAR	blockage.	
Hypothetically,	 an	 NMDAR	 antagonist	 that	 maintains	 activity	 at	
normal physiological levels would prevent side effect while also at-
tenuating OIH. The endocannabinoid system has recently emerged 
as	an	endogenous	regulator	of	NMDAR	activity	and	studies	have	ob-
served CB1	 receptors	directly	 interacting	with	NMDARs,	 reducing	
their activity.103 Furthermore, CB1 receptors are expressed in the 
DH.104 Therefore, cannabinoids may also be beneficial for reducing 
OIH.	Alternatively,	 EAAT2	activators	may	have	a	 role	 in	 reversing	
OIH. The β-	lactam	antibiotic	ceftriaxone	upregulates	spinal	EAAT2	
in an animal model of multiple sclerosis, and reverses the associated 
hyperalgesia.105 Further experiments to confirm these findings in 
animal	models	 of	OIH	 are	 required.	Nonetheless,	 EAAT2	 also	 ap-
pears a promising target for therapeutic intervention.
7  |  RECEPTOR AND CELLUL AR 
SIGNALING OF TOLER ANCE/OPIOID - 
INDUCED HYPERSENSIT VIT Y
MOR activation leads to a variety of signaling cascades and recep-
tor adaptations and some may be good pharmacological targets 
(Figure 8, Table 1 and 2) to improve the opioid side- effect profile 
and attenuate the development of tolerance and OIH.
A	remaining	mystery	in	the	development	of	analgesic	tolerance	
and OIH is the link between acute opioid signaling outcomes and 
the establishment of neuronal adaptations observed chronically. 
The development of many novel experimental drugs relies heavily 
on observed empirical data, with little mechanistic insight into why 
they work. For example, the role of B- arrestin- dependent signaling 
pathways is not clear (Table 2). Bohn et al. found attenuated analge-
sic tolerance to morphine in β- arrestin2 knockout mice, but similar 
knockouts did not alter tolerance to fentanyl.119 Similar differences 
have been observed for the respiratory depression and GI symptoms 
in arrestin knockout mice.120,121 The mechanisms underlying these 
discrepancies are still not clear, but it is becoming increasingly appar-
ent that attributing the adverse effects of MOR ligands to arrestin 
signaling may represent an oversimplification of the pathways.122,123 
Instead, recent evidence supports a role of G- proteins and arrestin 
signaling pathways in both the antinociceptive and the major side 
effects associated with MORs.
7.1  |  Development of novel biased opioid receptor 
ligands to improve opioids
The two most prescribed “strong opioids” in the UK are morphine 
and fentanyl. Fentanyl was synthetically developed with a higher 
affinity for MOR, with the intention that it would make for an 
F I G U R E  8 The	various	signaling	outcomes	following	MOR	activation.	G-	protein-	dependent	signaling	following	MOR	activation	involves	
the G- protein subunits pre- bound to the receptor, in the case of MOR, this is usually the Gαi and Gβγ	subunits.	Acutely,	MOR	activation	
inhibits	adenylyl	cyclase	(AC)	through	Gαi,	but	chronic	MOR	activation	appears	to	over-	activate	AC.	Desensitization,	internalization,	
recycling, and downregulation involve agonist- induced receptor phosphorylation, for example, through GRK. β- arrestin is recruited by 
phosphorylated residues of MOR. β- arrestin binding can trigger clathrin- mediated internalization of the receptor. MORs in endosomes 
can either be recycled to the plasma membrane or broken down (downregulation). β- arrestin can act as a scaffold to activate G- protein- 
independent signaling cascades (in red), for example, extracellular signal- regulated kinases (ERKs), c- Jun N- terminal kinases (JNKs), Src, and 
PKC106
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improved opioid. However, clinical evidence has not supported this, 
suggesting similar analgesic efficacies and tolerance development 
between the two opioids. More recently, a range of experimental G- 
protein/βarr2 biased MOR agonists has been developed and tested 
in mouse models, with the hope that there may be an optimum ratio 
of G- protein:B- arrestin signaling that would result in an “improved” 
opioid.124 Bias is related to different conformational states of the 
receptor, triggered by structural variations of the ligand and the 
transducers present.125	 Agonists	 highly	 biased	 toward	 G-	proteins	
with poor recruitment of B- arrestin2 appear to have more favorable 
properties, including higher antinociceptive potential and attenu-
ated development of tolerance.
One	such	MOR	G-	protein-	biased	ligand,	TRV130,	was	shown	
to cause less GI dysfunction and respiratory depression than 
morphine at equianalgesic doses in rats.121 Preclinical data of 
TRV130	suggested	it	may	be	a	safer	and	less	tolerant	prone	opi-
oid for treating chronic pain. Despite promising preclinical data, 
TRV130	 completed	 phase	 III	 clinical	 trials	with	 underwhelming	
results, demonstrating only a trend toward reduced side ef-
fects but no significant difference compared with morphine.126 
Therefore, optimizing bias factor alone may not be enough to 
improve opioids.
7.2  |  Peripheral/central site of action alters the 
side- effect profile of opioids
The distribution of opioids in the body following systemic admin-
istration impacts its outcomes. Peripherally restricted opioids that 
have a poor affinity for crossing the blood- brain barrier would be 
expected to develop less analgesic tolerance and respiratory depres-
sion as these are largely centrally mediated side- effects. However, 
peripherally restricted opioids do not appear to offer the same 
level of analgesic coverage for painful conditions as centrally acting 
Protein 





Refer to Section 6.2.2
Gi/Gs Naïve and acute 
MORs are 
coupled to Gi. 





Switch of the MOR- 
coupled G- protein 
from Gi to Gs in 
some spinal dorsal 
horn neurons, 
reversing the 




Targeting Gs itself will 
be associated with 
too many side effects 
not related to MOR. 
Enhanced activity of 
the pronociceptive 
adrenomedullin	(AM)	
can induce the switch 
from Gi to Gs- coupled 
MORs108 and this 
represents a more 
specific target to 
attenuate tolerance.
GRK/β- arrestin N/A In theory, 
desensitization of 
MOR (uncoupling 
of G- proteins to 
the receptor) and 
downregulation 




Desensitization is an 
acute phenomenon 
and occurs as 
part of the normal 
physiological response 
to GPCR activation. 
It is unlikely to 
contribute to the 




of MOR has not 
been observed in 
regions important for 
analgesia.
Morphine tolerance is 
associated with a 
decrease in opioid- 
mediated inhibition of 
GABA	release	that	is	
not a result of MOR 
desensitization.109
TA B L E  1 Summary	of	the	proteins	
involved in G- protein- dependent signaling 
and desensitization, internalization and 
downregulation, and their suitability 
as pharmacological targets to improve 
opioids
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opioids. Therefore, peripherally acting opioids may only be useful in 
pain- causing conditions lacking central sensitization.127 Herkinorin, 
a novel MOR selective G- protein- biased ligand, has a reduced toler-
ance profile and remains efficacious in rats made tolerant to chronic 
morphine, but its effects are peripherally restricted to the site of 
injection.128
7.3  |  Opioid kinetics
Bias is not the only factor that can alter the signaling outcome of 
a GPCR ligand. The kinetics of the drug, for example, its residual 
time (the time the drugs spends bound to the receptor), also ap-
pear	 important;	 buprenorphine	 and	 TRV130	 both	 have	 similar	G/
Barr- biases, but buprenorphine dissociates significantly slower from 
MORs	and	has	an	18x	higher	residence	time	compared	to	TRV130.129 
This difference could potentially lead to significantly different clini-
cal effects, such as the lower respiratory depression reported with 
buprenorphine.130 The effect of residual time on opioid efficacy has 
not yet been researched but this may be another parameter that re-
quires fine optimization.
Taken together, optimizing the bias, the residual time and the 
degree of central/peripheral action may be the next step in devel-
oping the “perfect” opioid agonist. The development of novel opi-
oids, such as endorphin derivatives that induce less tolerance with 
no significant OIH or glial activation,131 and biased- MOR agonists, 
indicates that opioids possessing good analgesic properties with re-
duced OIH and tolerance is possible.
8  |  CONCLUSION
Chronic pain is not merely prolonged activation of normal pain path-
ways, but instead reflects plasticity in both peripheral and central 
neuronal	circuits.	Likewise,	long-	term	opioid	signaling	is	not	simply	
inhibition of afferent pain signaling but involves adaptive changes in 
all the major pain processing pathways, some of which resemble the 
changes that occur in chronic pain.
As	a	result	of	the	severe	side-	effect	associated	with	opioids,	much	
of pain research over the last decades has attempted to replace opi-
oids, mostly with little fruition. Perhaps it is time to take a step back 
and look at improving opioids, harnessing their undeniable analgesic 
efficacy	of	the	opioid-	responsive	system.	A	variety	of	novel	targets	
have been discussed that, when co- administered with an opioid, may 
allow suffers of chronic pain to achieve effective long- term pain relief. 
Furthermore, the development of new opioid agonists with more de-
sirable properties is also a possibility. Tolerance and OIH are just two 
of the factors that plague opioid usage. Research must also be done 
into	minimizing	opioid	addiction	and	physical	dependence.	Addiction	
involves of elements of biology but also behavioral, societal, and 
TA B L E  2 Summary	of	the	proteins	involved	in	G-	protein-	independent	signaling	their	suitability	as	pharmacological	targets	to	improve	
opioids
Protein implicated Role in analgesia Role in tolerance/OIH Suitable pharmacological target?
β- arrestin N/A N/A Provides a scaffolding role and is not 
a signaling molecule in its own 
right, therefore unlikely to be a 
good pharmacological target.110
Mitogen- activated protein 
kinase pathways (ERK and 
JNK)
Contribution toward 
antinociception appears to 
my both agonist and location 
dependent.111
Similar to their role in 
antinociception, ERK and 
JNK’s role in tolerance is 
agonist and cell location 
dependent.111,112
Differential functions of ERK and JNK 
make this a poor pharmacological 
target based on our current 
molecular understanding of their 
signaling pathways.
Src Src activation appears to have 
no effect on antinociceptive 
effect113
The MOR- B- arrestin- Src 




GRK2/3) implicated in 
tolerance and OIH114,115
Src kinase inhibition attenuates 
morphine tolerance.113 Inhibitors 
of Src (e.g., Dasatinib) are already 
used clinically for leukemia, so 
their safety in humans is already 
established.
PKC N/A PKC has been implicated in 
acute desensitization of 
MOR in response to specific 
opioid agonists, analogous 
to GRK116; PKC activation by 
MORs	may	sensitize	NMDAR	
receptors co- expressed on 




appear significant toward 
chronic opioid tolerance. While 
there may be some potential 
in directly targeting PKC to 
reduce activation of downstream 
effectors	(e.g.,	NMDAR),	no	PKC	
inhibitor has been approved 
for clinical use.118 Targeting the 
downstream effectors directly 
may be more successful
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other social factors such as education, so any improved opioid para-
digm must involve more than just pharmacological improvements.132 
For instance, a greater involvement of healthcare professionals, in-
cluding psychiatrists, may be beneficial in long- term opioid users.133 
By championing multiple avenues of investigation such as improving 
opioids by minimizing OIH and tolerance as discussed in this review, 
improving opioid addiction and physical dependence, and continuing 
work on non- opioid alternatives, the likelihood of improving analgesic 
treatment becomes ever greater.
MOR variants within individuals result in varying responses to 
opioids, and differing mechanisms and propensities to tolerance and 
OIH.134	As	such,	it	is	likely	that	improving	opioid	treatment	will	vary	
on a case by case basis. In the future, trialing each patient on a spe-
cific	“improved”	opioid	agonist	with	an	adjuvant	(e.g.,	AC	inhibitors,	
cannabinoids,	 CCK	 receptor	 antagonists,	 or	 NMDAR	 antagonists),	
and refining this combination over time, will likely result in the best 
combination for the individual.
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